Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes

作者
Thibaud Mathis,Frank Gerhard Holz,Sobha Sivaprasad,Young Hee Yoon,Nicole Eter,Lee-Jen Chen,Adrian CH Koh,Eduardo Cunha de Souza,Giovanni Staurenghi
出处
期刊:Eye [Springer Nature]
卷期号:37 (9): 1758-1765 被引量:61
标识
DOI:10.1038/s41433-022-02231-y
摘要

The aim of this review is to identify the common characteristics and prognoses of different subtypes of neovascular age-related macular degeneration (nAMD). We also propose recommendations on how to tailor treatments to the subtype of neovessels to optimise patient outcomes. The authors, selected members of the Vision Academy, met to discuss treatment outcomes in nAMD according to macular neovascularisation (MNV) subtypes, using evidence from a literature search conducted on the PubMed database (cut-off date: March 2019). This review article summarises the recommendations of the Vision Academy on how the characterisation of MNV subtypes can optimise treatment outcomes in nAMD. The identification of MNV subtypes has been facilitated by the advent of multimodal imaging. Findings from fluorescein angiography, indocyanine green angiography and spectral-domain optical coherence tomography collectively help refine and standardise the determination of the MNV subtype. To date, three subtypes have been described in the literature and have specific characteristics, as identified by imaging. Type 1 MNV is associated with better long-term outcomes but usually requires more intense anti-vascular endothelial growth factor dosing. Type 2 MNV typically responds quickly to treatment but is more prone to the development of fibrotic scars, which may be associated with poorer outcomes. Type 3 MNV tends to be highly sensitive to anti-vascular endothelial growth factor treatment but may be associated with a higher incidence of outer retinal atrophy, compared with other subtypes. Accurately assessing the MNV subtype provides information on prognosis and helps to optimise the management of patients with nAMD.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
coff完成签到,获得积分10
2秒前
3秒前
研友_ZG4ml8发布了新的文献求助10
3秒前
学术的刘完成签到,获得积分10
3秒前
Allen完成签到,获得积分10
4秒前
牧芷珊完成签到,获得积分10
4秒前
阿柠完成签到,获得积分10
4秒前
研友_Zbb4mZ完成签到,获得积分10
4秒前
三七二一完成签到,获得积分10
4秒前
5秒前
JamesPei的应助被爱在西元前采纳,获得10
5秒前
奋斗蝴蝶发布了新的文献求助10
6秒前
陈zw完成签到,获得积分10
6秒前
6秒前
zzzzlllll完成签到,获得积分10
6秒前
Sue完成签到,获得积分10
7秒前
rrr完成签到,获得积分10
7秒前
ZYX完成签到,获得积分10
7秒前
喜悦白玉发布了新的文献求助10
8秒前
ZJ完成签到,获得积分10
8秒前
8秒前
wanci的应助被瘦瘦滢采纳,获得10
8秒前
拉普拉斯开始变换完成签到,获得积分10
8秒前
molihuakai的应助被方苠采纳,获得10
8秒前
feiyue126发布了新的文献求助10
8秒前
9秒前
skmksd发布了新的文献求助10
9秒前
登山者完成签到,获得积分10
9秒前
幸运鱼完成签到,获得积分10
9秒前
小明同学呀完成签到,获得积分10
10秒前
yi完成签到,获得积分10
10秒前
10秒前
joyli完成签到,获得积分10
10秒前
阿白完成签到,获得积分10
11秒前
11秒前
李健的小迷弟的应助被Lily采纳,获得10
11秒前
嘻嘻哈公主完成签到 ,获得积分20
11秒前
哈尼完成签到,获得积分10
11秒前
酷酷冷亦完成签到,获得积分10
11秒前
苹果骑士完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039